Sirolimus (Rapamune) News, Updated Regularly

We have no matching items at this time. Please check back shortly.

Are you looking for additional Rapamune (Sirolimus) news? Try our new "Sirolimus News Focus" area.

Are you looking for additional Rapamune (Sirolimus) information? Try our new "Sirolimus Related Blog Entries" area.

Off-site Sirolimus (Rapamune) Links, User Submitted

The following links have been collected through user bookmark submission in the Sirolimus_Rapamune category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Wed Oct 29

• The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.: Although DNA damaging agents have revolutionized chemotherapy against solid tumors, a narrow therape

Thu Sep 25

• The mTOR pathway 2008
• Image:MTOR-pat hway-betz.jpg - Wikipedia, the free encyclopedia

Mon Mar 10

• Sirolimus - Yahoo! Health: What is sirolimus? Sirolimus lowers your body's immune system. The immune system helps your body fight infections...
• Sirolimus - Wikipedia, the free encyclopedia: Sirolimus is a relatively new immunosuppress ant drug used to prevent rejection in organ transplantatio n, and is especially useful in kidney transplants. Sirolimus is a macrolide. It is marketed under the trade name Rapamune by Wyeth.
• Rapamune Consumer Information: What are some possible side effects of Rapamune? (This is not a complete list of side effects reported with Rapamune. Your health care provider can discuss with you a more complete list of side effects.) Rapamune is an immunosuppress ant drug. Immunosu
• MedlinePlus Drug Information: Sirolimus: Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppress ants. It works by suppressing the body's immune system.
• Sirolimus (Oral Route) - MayoClinic.com: US Brand Names * Rapamune Description Sirolimus belongs to a group of medicines known as immunosuppress ive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.

Tue Sep 25

• Safety and Efficacy of Sirolimus- and Paclitaxel-Elu ting Coronary Stents || NEJM 2007: Stone GW, Moses JW, Leon MB, Colombo A, Schampaert E, Grube E, et al.
• C-SIRIUS | Canadian study of the sirolimus-elut ing stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS): Schampaert E, Cohen EA, Popma JJ, et al.
• Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Uns ettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) | A: Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Uns ettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) C

Fri Sep 21

• Las endoprótesis que liberan sirolimus superan a las de paclitaxel - DiarioMedico.c om

Sun Jul 15

• Meta-Analyses Find Increased Death and MI with Cypher Stent =|= CME Teaching Brief® =|= MedPage Today

Wed Jul 11

• ClinicalTrials .gov =|= ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial: Evaluation of Cypher Sirolimus Eluting Stent in Patients Undergoing Elective Revascularizat ion of Nonacute Total Coronary Occlusions (TCO). Cordis Corp. Columbia Presbyterian, NYC. 2006-2011. (Not currently recruiting)

Off-site Sirolimus Research Links

If you still need additional information on Sirolimus then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.